Surrogate End Points in Pulmonary Arterial Hypertension: Assessing the Response to Therapy - 09/08/11
Doi : 10.1016/j.ccm.2006.11.005
Jennifer L. Snow, MD a, Steven M. Kawut, MD, MS b, c, ⁎ 
a Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Pennsylvania School of Medicine, 844 West Gates Building, 3400 Spruce Street, Philadelphia, PA 19104, USA
b Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, College of Physicians and Surgeons, Columbia University, PH 8E, Room 101, 622 W. 168th Street, New York, NY 10032, USA
c Department of Epidemiology, Joseph L. Mailman School of Public Health, Columbia University, 722 W. 168th Street, New York, NY 10032, USA
Corresponding author. Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, Columbia University College of Physicians and Surgeons, PH 8E, Room 101, 622 W. 168th Street, New York, NY 10032.Abstract |
Recent discoveries in the disease pathophysiology of pulmonary arterial hypertension have been translated into effective therapies tested in clinical trials. The studies have focused on surrogate and intermediate end points, thought to reflect quantity and quality of life, respectively. The authors present the necessary requirements for establishing the reliability and validity of such end points before they may be used dependably. The authors also review the available data, strengths, and weaknesses of potential end points in pulmonary arterial hypertension.
Le texte complet de cet article est disponible en PDF.Plan
| Supported in part by NIH grants K23 HL67771, RO3 DK064103, RO1 HL086719, and RO1 HL082895. |
© 2007
Elsevier Inc. Tous droits réservés.
Vol 28 - N° 1
P. 75-89 - mars 2007 Retour au numéro
Article précédent
- Diagnosis of Pulmonary Arterial Hypertension
- Terence K. Trow, John R. McArdle
- Standard Therapies for Pulmonary Arterial Hypertension
- Shoaib Alam, Harold I. Palevsky
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?